Cladribine Merck Oral Multiple Sclerosis therapy

Merck has developed oral therapy for relapsing forms of multiple sclerosis (MS). Cladribine is earlier known for treatment of cancer (leukemia) in intravenous administration. Now Merck licensing from Ivax (Teva subsidiary) has developed oral therapy for MS.

This product is now at pre-registration stage in USA and approved in Russia and Australia. Europe’s CHMP has given negative opinion for Cladribine oral therapy (Press release).

Patent: Ivax has two patent application on oral formulation of Cladribine, which are WO2004087101 & WO2004087100. Probably these patent applications may cover marketed formulation of Cladribine.

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s